InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Blogger Profile

Patrick Wingrove

Email: patrick.wingrove@managingip.com
Location:
Company:
Author link:

Blogger Posts

  • Thu, 21 March 2019

    In-house IP roundup: blue-v-blue biologic litigation rises; UPC apathy after new complaint listing; businesses shed patents for cost savings

    Patent Strategy, a new service from Managing IP, rounds up the latest news and analysis from patent-focused businesses

  • Thu, 14 March 2019

    In-house IP roundup – Generics say SPC Waiver will save money but increase litigation, counsel share M&A tips

    Patent Strategy, a new service from Managing IP, rounds up the latest news and analysis from patent-focused businesses

  • Fri, 08 March 2019

    In-house IP roundup – Eligibility test stalls US innovation, connected car tech licensing and litigation tensions

    Patent Strategy, a new service from Managing IP, rounds up the latest news and analysis from patent-focused businesses

  • Fri, 01 March 2019

    In-house IP roundup – AI partnership concerns, how counsel evaluate external lawyers, generics discuss major patent cases

    Patent Strategy, a new service from Managing IP, rounds up the latest news and analysis from patent-focused businesses

  • Mon, 25 February 2019

    In-house IP roundup – CRISPR patent pool unlikely, AI to streamline patenting, big data drives enforcement

    Patent Strategy, a new service from Managing IP, rounds up the latest news and analysis from patent-focused businesses

  • Fri, 22 February 2019

    Download the full AI and patents survey report

    Patent Strategy, a new in-house-sourced service, surveyed more than 60 in-house patent lawyers across different industry sectors in Europe, North America and Asia throughout January 2019 to reveal market attitudes and concerns around AI and patents

  • Thu, 21 February 2019

    CRISPR patent pool unlikely, say therapeutics businesses

    Patent counsel from Novartis, Celyad and five other biotech and pharmaceutical firms say that they are open to a commercial CRISPR-Cas9 licensing platform, but that the establishment of a successful pool is improbable because of financial and practical barriers

  • Mon, 18 February 2019

    Poll: over half of businesses to drive patenting efficiencies with AI

    Part three of Patent Strategy’s survey of more than 60 in-house lawyers shows that more than half of businesses will use artificial intelligence to power up their patenting process. Sources say that the other half may be “missing a trick”

  • Fri, 15 February 2019

    Tackling Brexit confusion a priority for new CIPA president

    Julia Florence, who is new president of the UK’s Chartered Institute of Patent Attorneys and was senior patent counsel at GSK until 2018, says educating businesses abroad about Brexit and the EPO, and encouraging new and diverse talent to the IP profession are key tasks for her organisation

  • Wed, 23 January 2019

    Prior art shortage could strain US cannabis innovation

    Counsel at Steep Hill Labs, Phylos Bioscience, Medicinal Genomics and the Open Cannabis Project explain how cannabinoid innovation could be blocked by overly broad or weak patents at the USPTO, and what the industry is doing to develop, collect and record prior art

  • Tue, 22 January 2019

    Take our survey on artificial intelligence and patents

    Managing IP invites its in-house counsel readers to take its survey on patenting AI, patenting AI-invented innovations and how AI could streamline the patenting process. Help inform the industry and, in the process, inform yourselves

  • Wed, 16 January 2019

    China patent flood stifles foreign filer freedom

    Counsel at the ZF Group, Philips, Siemens and elsewhere explain how the surge of domestic patents filings in China is making freedom-to-operate searches more difficult, and what they’re doing about this challenge

  • Tue, 15 January 2019

    EPO AI guidelines “give clarity and direction”, say in-house counsel

    Lawyers from IBM and other artificial intelligence-focused businesses have welcomed the EPO’s new guidelines, but say kinks in the examination approach to the technology in Europe and elsewhere need to be ironed out and then harmonised

  • Thu, 10 January 2019

    Medical device partnership surge exacerbates patent negotiation and FTO challenges

    In-house counsel at Philips, Biotronik and elsewhere explain how their growing number of tech partnerships is affecting medical device patent negotiations, and how the surge of new players into the market is making freedom-to-operate harder to diagnose

  • Wed, 09 January 2019

    Medical device partnership surge exacerbates patent negotiation and FTO challenges

    In-house counsel at Philips, Biotronik and elsewhere explain how their growing number of tech partnerships is affecting medical device patent negotiations, and how the surge of new players into the market is making freedom-to-operate harder to diagnose

  • Mon, 07 January 2019

    PGR popularity tipped to soar among US biosimilar makers

    In-house counsel say they’re ready to embrace post-grant reviews as a new wave of biologic patents filed after 2012 surges towards the industry

  • Wed, 12 December 2018

    EPO ruling sows patenting doubts for seeds companies

    In-house counsel say the EPO Technical Board of Appeal’s conclusion that plants made from essentially biological processes are patentable could usher in another decade of protection uncertainty in the industry

  • Wed, 12 December 2018

    EPO ruling sows patenting doubts for seeds companies

    In-house counsel say the EPO Technical Board of Appeal’s conclusion that plants made from essentially biological processes are patentable could usher in another decade of protection uncertainty in the industry

  • Tue, 11 December 2018

    UK pregabalin ruling “increases patent applicant burden”, say drug companies

    Innovator and generics drug companies share their reaction to the judgment in Warner-Lambert v Generics. One in-house lawyer explains that it will be particularly detrimental to small innovator companies and “does not reflect the scientific reality of drug development”

  • Thu, 06 December 2018

    In-house counsel reveal how they build internal IP awareness

    Intellectual property departments in patent-focused companies are driving greater integration of IP through implementing better communication and education mechanisms

  • Wed, 05 December 2018

    European GMO ruling stems CRISPR patent pool efforts

    Plans for a CRISPR patent pool in the agricultural sector have been stifled by the ECJ's July ruling that crops derived from the technology are genetically modified organisms. In-house counsel say it has made those patents less valuable

  • Wed, 28 November 2018

    Patent filing strategies to stay ahead in growing markets

    In-house counsel are trying to break down silos between business departments to help them work out where they will and won’t need patents in the next five to 10 years

  • Tue, 27 November 2018

    Budget pressures pushing patent processes in house

    Technology, life sciences and manufacturing companies say they’re increasingly bringing patent processes in house to make them more cost efficient. The challenge is working out when a function is better done internally, outsourced to private practice or split between the two

  • Fri, 23 November 2018

    Tech convergence drives autonomous car patent licensing tension

    A sudden influx of new players with standard essential patents into the automotive market is causing conflict between automotive companies and their driverless-car suppliers over who should take a licence in the supply chain

  • Wed, 21 November 2018

    China patent improvements increasing foreign filers’ confidence

    While patent-focused companies continue to be wary of the relatively untested Chinese patent system, developments in the country’s IP offices and courts are helping

  • Tue, 13 November 2018

    Biosimilar makers forgo “cut-and-thrust” launch tactics

    Large generics drug companies are becoming more diligent and cautious about clearing patent thickets blocking biosimilars than they have traditionally been with small molecule products

  • Mon, 05 November 2018

    Unwired Planet is “massive time and money saver”, say telecoms and car companies

    Large telecoms companies say the UK Court of Appeal’s decision that global licences for SEPs can be FRAND streamlines licensing while automotive firms believe it helps benchmark component prices. But more still needs to be clarified

  • Fri, 02 November 2018

    Seed patent growth prompts litigation and licensing fears

    European seed companies prepare for licensing and litigation difficulties as technology allows them to patent more inventions and threatens to stifle the industry’s strong sharing culture

  • Fri, 02 November 2018

    Patent portfolio pressure – how counsel try to do more with less budget

    In-house counsel from confectionery, biopharmaceutical, telecommunications, technology, plastics and medical research companies explain how they’re measuring patent worth to find cost-saving wins

  • Wed, 31 October 2018

    Seed patent growth prompts litigation and licensing fears

    European seed companies prepare for licensing and litigation difficulties as technology allows them to patent more inventions and threatens to stifle the industry’s strong sharing culture

  • Wed, 31 October 2018

    Patent portfolio pressure – how counsel try to do more with less budget

    In-house counsel from confectionery, biopharmaceutical, telecommunications, technology, plastics and medical research companies explain how they’re measuring patent worth to find cost-saving wins

  • Thu, 25 October 2018

    Life sciences firms reveal how AI could disrupt patent strategies

    In-house counsel at life sciences companies reveal how machine-learning innovations are driving uncertainty over future filing strategies

  • Thu, 25 October 2018

    Patent advisers pressured by in-house strategy changes

    Counsel from chemicals, seeds, technology, confectionery, pharmaceutical and medical research firms share what they increasingly look for from outside counsel with Managing IP

  • Popular Posts

    Blog Archive

    IP-related blogs

    1709 Copyright Blog

    Afro-IP

    AIA blog

    Art and Artifice

    China IPR

    Class 99

    Domain Incite

    FOSS Patents

    Green Patent Blog

    Incontestable

    IP CloseUp

    IP Dragon

    IP finance

    IP Kat

    IP Komodo

    IP tango

    IP Watchdog

    IPEG

    MARQUES Class 46

    Orange Book Blog

    Patent Baristas

    PatentlyO

    PatLit

    SPC Blog

    Spicy IP

    The Trademark Blog

    The TTABlog